CompletedPhase IInterventional

Phase I Trial: Quotient Code QSC302899

This is a Phase I trial, which means it's one of the first studies in humans for a new treatment called QSC302899. Usually, these early studies focus on checking if a treatment is safe and finding the right dose. For now, the full details about the study, such as the exact conditions it's for, who can take part, and what the treatments involve, are not available to the public. These details will be published within 30 months after the trial finishes. This trial is currently open to men between the ages of 30 and 65.

At a glance

Status

Completed

Phase

Phase I

Sponsor

Shionogi B.V.

Enrolment target

Start

15 Apr 2025

Estimated completion

08 Jul 2025

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

What is this study about?

This study is a very early step in testing a new potential treatment, which has been given the code QSC302899. In medical research, trials are typically done in phases. This particular study is a 'Phase I' trial. This means it's usually one of the very first times a new medicine or treatment is given to people.

The main goals of a Phase I trial are typically to see if the treatment is safe, to understand how it affects the body, and to find the best dose to use in future studies. It's not usually about whether the treatment can cure a disease, but rather making sure it's safe enough to continue testing.

At this stage, the company running the trial has decided to keep some of the main details private for a while. This is quite common in early-stage research to protect their findings. They have confirmed that all the specific information about who can join, what the study is about, and what medicines are being tested will be made public within 30 months (that's two and a half years) after the study has officially finished. For now, we know the study is looking for men aged between 30 and 65.

Key takeaways

This is a Phase I trial, an early-stage study of a new treatment (QSC302899).
Its main aim is usually to check safety and find the right dose.
Full details about the study won't be public until after it's finished (within 30 months).
Only men aged 30 to 65 are currently eligible to take part.
Participation helps future medical knowledge, but direct health benefits for participants are not guaranteed.
You can withdraw from any study at any time.

Who may be eligible?

This study is specifically looking for men who are between 30 and 65 years old. If you are a man in this age group, you might be able to take part.

At the moment, we don't have all the specific details about other health conditions or factors that might mean you can or cannot join the study. These are called 'inclusion' and 'exclusion' criteria, and they help make sure the study is safe for everyone involved and that the results are clear.

The full list of rules about who can join will be made public within 30 months after the study ends. If you're interested, you would need to speak with the study team who can check all your details against the full criteria.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you a man?
Are you between 30 and 65 years old?
Do you generally feel healthy?
Are you able to commit to regular study appointments?

Answer every question to see your result.

What does participation involve?

Information about what taking part in this specific trial involves, such as the number of visits, what tests you might have, how the medicine is given, and how long you would be followed up for, isn't publicly available yet. This type of detail will usually include things like how often you'd need to come to a clinic, whether you'd take medication at home or in the clinic, and any monitoring you'd have.

Because this is a Phase I study, it often means more frequent visits to the study centre, and careful monitoring, especially when the treatment is first given. The total length of your participation, including any follow-up, will be clearly explained by the study team if you are found to be a suitable candidate.

Potential risks and benefits

Potential benefits of taking part in a Phase I trial are generally not direct medical benefits to the participant, as the main goal is to test safety in healthy volunteers or patients with stable conditions. However, participants contribute to advancing medical knowledge that could help others in the future. As with any new medicine, there could be risks of side effects, which are not yet fully known. The study team will explain all known and potential risks in detail, and you will always have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Quotient Sciences Limited
City only
Nottingham, United Kingdom

Common questions

What is a Phase I trial?

A Phase I trial is the first step in testing a new medicine or treatment in people, mainly to check if it's safe and to find the right dose.

When will more information about this trial be available?

The full details about this trial will be made public within 30 months (two and a half years) after the study has finished.

Can women take part in this study?

No, this study is currently only open to men.

What is the age range for participants?

Participants must be between 30 and 65 years old.

Will I receive direct medical benefit from this trial?

Phase I trials primarily focus on safety, so direct medical benefits for participants are not the main goal. However, you would be helping advance medical research.

How to find out more

Cornelia Krueger

regulatory.affairs@shionogi.eu +44 (0)20 3053 4200 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.